Change from baseline in hematologic parameters and biomarkers. (A) Change from baseline in hemoglobin levels. Mean hemoglobin values at baseline were at the lower limit of the normal range and improved to within normal limits at month 9. Significant increases in mean hemoglobin levels were observed between baseline and month 9 for both dose groups (see “Results”) and for anemic patients (see “Results”). (B) Change from baseline in platelet counts: a significant increase in platelet counts from baseline was observed (see “Results”) in the 60 U/kg dose group at month 9 (mean increase = 41 494/mm³) and in the 30 U/kg dose group (mean increase = 11 427/mm³). (C) Gaucher disease severity as evidenced by a decrease in chitotriosidase levels at month 9. Disease severity and response to treatment was monitored by measurement of chitotriosidase levels before first-dose administration and at visits 7, 14, and 20. All patients achieved decreases in chitotriosidase levels by month 9. The mean decrease in chitotriosidase levels was ∼ 50% from baseline by month 9 (P < .0001 at 30 U/kg/infusion and P = .0016 at 60 U/kg/infusion). The error bars represent SE.